Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Politics

Sanders targets pharma CEOs to testify in Senate, but some see ‘retaliation’ for lawsuit against Biden admin

by January 20, 2024
January 20, 2024
Sanders targets pharma CEOs to testify in Senate, but some see ‘retaliation’ for lawsuit against Biden admin
Read this article for free!
Plus get unlimited access to thousands of articles, videos and more with your free account!
Please enter a valid email address.
By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your email and follow the instructions provided.

Sen. Bernie Sanders, I-Vt., announced this week he plans to hold a vote on Jan. 31 to subpoena the CEOs of two big Pharma companies for a hearing on drug pricing in front of the Health, Education Labor & Pensions (HELP) Committee after they refused to testify last year.

The subpoenas for Johnson & Johnson CEO Joaquin Duato and Merck CEO Robert Davis would have them testify about why their costs for medicine are ‘substantially higher’ compared to other countries, the announcement said. 

But some executives see the pending subpoenas as a form of retaliation for a court battle over Medicare price negotiations.

‘It is absolutely unacceptable that the CEOs of Johnson & Johnson and Merck have refused an invitation by a majority of members on the HELP Committee to appear before Congress about the outrageously high price of prescription drugs,’ Sanders said. ‘These CEOs may make tens of millions of dollars in compensation. The pharmaceutical companies they run may make billions in profits.’

In November, Sanders requested Duato and Davis for testimonies on drug pricing, but they insisted that a ‘senior pharmaceutical executive best positioned to address and provide Johnson & Johnson’s position regarding the issues’ should instead appear, according to a letter Johnson & Johnson attorney Brian D. Smith sent to Sanders this week in response to the subpoena announcement. 

‘Johnson & Johnson offered to make available for the hearing the senior pharmaceutical executive best positioned to address and provide Johnson & Johnson’s position regarding the issues posed in your invitation letter,’ Smith wrote. ‘Throughout these discussions, Johnson & Johnson has also made clear its concerns with the direction the Committee is taking with the hearing, including the reasons that the company’s chief executive is not the appropriate witness for this hearing. We appreciate the opportunity to reiterate the concerns that we have previously conveyed to your staff over the past three months, and we urge you to consider permitting the Committee to hear from the appropriate executive for these topics.’

The two Pharma companies, alongside others, are currently suing to freeze Medicare drug price negotiation under Biden’s Inflation Reduction Act. Merck Executive Vice President Jennifer Zachary also sent a letter to Sanders this week suggesting the request to have the CEOs testify in front of the Senate panel is a form of ‘retaliation’ for the ongoing lawsuit.

 ‘We appreciate that many Committee members have expressed their disagreement with our lawsuit, and we respect their good-faith views. That said, your public criticisms of the Companies for challenging the IRA and comments regarding hearing witnesses indicate that the invitations to testify have been extended as retaliation for the Companies’ exercise of their constitutional right to seek relief in court,’ Zachary wrote. 

Joe Grogan, who served as a domestic policy advisor to former President Trump, told Fox News Digital in an interview that ‘CEOs are not the subject matter experts in the company who can explain all the different aspects of the pharmaceutical supply chain’ and negotiations with other governments.

‘To put a fine point on it, it’s completely un-American,’ Grogan said. ‘I mean, these companies have every right to avail themselves of the courts, they have every right to sue and to be for him to target these three companies is not a coincidence.’

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
A Biotech Stock with a Breakout on the Weekly and a Classic Retracement on the Daily
next post
Excelling in Marketing Management Assignments: Expert Insights on the Subject

You may also like

Numerous people visited Joe Biden’s house while classified...

January 13, 2023

Farm state Republicans appear skeptical about RFK Jr...

December 18, 2024

Pelosi university speech interrupted by anti-Israel agitators: ‘Warmonger’

April 27, 2024

JD Vance says Trump clashed with former officials...

October 27, 2024

LOCK HIM UP: Fauci’s Agency Has Tortured Animals...

December 5, 2022

GOP Sen. Ted Budd demands State Department roll...

October 24, 2023

Biden Admin Declassifies Bush and Cheney Post 9/11...

November 14, 2022

Stone Cold Crazy Kamala Harris: Diesel Powered School...

October 27, 2022

Hegseth bans future trans soldiers, makes sweeping changes...

February 10, 2025

New GOP bill would make Biden impose maximum...

October 21, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Firestarter: the London consultancy helping scale-ups build braver B2B brands

      August 28, 2025
    • Barclays exits Entercard joint venture with £200m sale to Swedbank

      August 28, 2025
    • Is Trump considering bold Africa play to push back on China, Russia and Islamic terrorists?

      August 28, 2025
    • ‘Gender bonus bias’ revealed as men nearly 1.5 times more likely to receive bonuses than women

      August 28, 2025
    • Four in five online small businesses expect growth despite UK economic headwinds

      August 28, 2025
    • Tesla sales slump 42% in Europe as BYD overtakes market share

      August 28, 2025

    Categories

    • Business (8,909)
    • Investing (2,246)
    • Politics (16,504)
    • Stocks (3,228)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved